MedKoo Biosciences

Oxidopamine HCl
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414672

CAS#: 28094-15-7 (HCl)

Description: Oxidopamine HCl is a neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.

Chemical Structure

Oxidopamine HCl

CAS# 28094-15-7 (HCl)

Instruction

Theoretical Analysis

MedKoo Cat#: 414672
Name: Oxidopamine HCl
CAS#: 28094-15-7 (HCl)
Chemical Formula: C8H12ClNO3
Exact Mass: 205.05
Molecular Weight: 205.640
Elemental Analysis: C, 46.73; H, 5.88; Cl, 17.24; N, 6.81; O, 23.34

Price and Availability

Size	Price	Availability
100mg	USD 350	2 Weeks
500mg	USD 950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Oxidopamine hydrochloride; Oxidopamine HCl; NSC233898; NSC-233898; NSC 233898; 6-OHDA

IUPAC/Chemical Name: 2,4,5-Trihydroxyphenethylamine hydrochloride

InChi Key: QLMRJHFAGVFUAC-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H11NO3.ClH/c9-2-1-5-3-7(11)8(12)4-6(5)10;/h3-4,10-12H,1-2,9H2;1H

SMILES Code: NCCC1=CC(O)=C(O)C=C1O.[H]Cl

Appearance: Solid powder

Purity: >97% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 205.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Pantic I, Cumic J, Skodric SR, Dugalic S, Brodski C. Oxidopamine and oxidative stress: Recent advances in experimental physiology and pharmacology. Chem Biol Interact. 2021 Feb 25;336:109380. doi: 10.1016/j.cbi.2021.109380. Epub 2021 Jan 13. PMID: 33450287.

2: Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res. 2007 Apr;11(3-4):151-67. doi: 10.1007/BF03033565. PMID: 17449457.

3: Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. Neurologia. 2017 Oct;32(8):533-539. English, Spanish. doi: 10.1016/j.nrl.2015.06.011. Epub 2015 Aug 21. PMID: 26304655.

4: Matsuura K, Kabuto H, Makino H, Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods. 1997 Apr 25;73(1):45-8. doi: 10.1016/s0165-0270(96)02211-x. PMID: 9130677.

5: Pantic I, Dimitrijevic D, Nesic D, Petrovic D. Gray level co-occurrence matrix algorithm as pattern recognition biosensor for oxidopamine-induced changes in lymphocyte chromatin architecture. J Theor Biol. 2016 Oct 7;406:124-8. doi: 10.1016/j.jtbi.2016.07.018. Epub 2016 Jul 16. PMID: 27424557.

6: Bouchatta O, Manouze H, Bouali-Benazzouz R, Kerekes N, Ba-M'hamed S, Fossat P, Landry M, Bennis M. Neonatal 6-OHDA lesion model in mouse induces Attention- Deficit/ Hyperactivity Disorder (ADHD)-like behaviour. Sci Rep. 2018 Oct 18;8(1):15349. doi: 10.1038/s41598-018-33778-0. PMID: 30337626; PMCID: PMC6193955.

7: Varešlija D, Tipton KF, Davey GP, McDonald AG. 6-Hydroxydopamine: a far from simple neurotoxin. J Neural Transm (Vienna). 2020 Feb;127(2):213-230. doi: 10.1007/s00702-019-02133-6. Epub 2020 Jan 1. PMID: 31894418.

8: Hsu SW, Hsu PC, Chang WS, Yu CC, Wang YC, Yang JS, Tsai FJ, Chen KY, Tsai CW, Bau DT. Protective effects of valproic acid on 6-hydroxydopamine-induced neuroinjury. Environ Toxicol. 2020 Aug;35(8):840-848. doi: 10.1002/tox.22920. Epub 2020 Mar 13. PMID: 32167238.

9: Cauli O, Morelli M. Caffeine and the dopaminergic system. Behav Pharmacol. 2005 Mar;16(2):63-77. doi: 10.1097/00008877-200503000-00001. PMID: 15767841.

10: Barilar JO, Knezovic A, Perhoc AB, Homolak J, Riederer P, Salkovic-Petrisic M. Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. J Neural Transm (Vienna). 2020 Feb;127(2):231-250. doi: 10.1007/s00702-020-02152-8. Epub 2020 Feb 6. PMID: 32030485; PMCID: PMC7035309.

Your view history

Oxidopamine HCl featured